IMTX / Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?

Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong more_horizontal

Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks in more_horizontal

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative t more_horizontal

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer more_horizontal

Immatics (IMTX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0. more_horizontal

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revision more_horizontal

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revision more_horizontal

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the more_horizontal